GlaxoSmithKline: Small Cell Lung Carcinoma trials

The registry lists 17 Small Cell Lung Carcinoma studies with GlaxoSmithKline as lead sponsor. 1 are open to participants now and 5 have results posted.

Phase 1 6Phase 2 6Phase 3 4No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]RecruitingNCT07099898Phase 3
• Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung CarcinomaTerminatedNCT02034123Phase 1Results posted
• A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other CancersCompletedNCT01587703Phase 1Results posted
• A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) PopulationTerminatedNCT01313663Phase 2Results posted
• Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung CancerCompletedNCT00698516Phase 2Results posted
• First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And ParaplatinCompletedNCT00316186Phase 2Results posted
• A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid TumorsWithdrawnNCT03266159Phase 2
• A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer SubjectsCompletedNCT02797977Phase 1/2
• A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid MalignanciesSuspendedNCT01604863Phase 1
• Regulatory Hycamtin(Oral) PMSCompletedNCT01037023
• SCOT Registry: Small Cell Lung Cancer Treatment and OutcomeCompletedNCT00997061
• Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung CancerCompletedNCT00320359Phase 3
• Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung CancerCompletedNCT00276276Phase 3
• A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid TumorsCompletedNCT00259935Phase 1
• A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid TumorsCompletedNCT00046111Phase 1
• Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive AdultsCompletedNCT00043927Phase 3
• The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)CompletedNCT00043862Phase 2